Fundraising Fox
/Companies
Sign in

Candid Therapeutics

San Diego, US · Founded 2024 · Delaware corporation · 38 employees on LinkedIn · 9 known investors

Find your way into Candid Therapeutics

Sign up to see every warm intro you have to Candid Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Candid Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells. The company focuses on creating therapies that are more effective and easier to administer than existing antibody and cell therapy approaches.

BiotechHealthtech

Founders & leadership

Candid Therapeutics was founded in 2024 by Ken Song and Kenneth Song, M.D..

KSKen Song
Ken SongChairman, President and CEOHe previously founded or led RayzeBio (a radiopharmaceutical company acquired by Bristol Myers Squibb), Ariosa Diagnostics (a prenatal diagnostics company acquired by Roche), and Metacrine, and trained in internal medicine and gastroenterology at UCSF and University of Washington.
KSKenneth Song, M.D.
Kenneth Song, M.D.Co-founder
AKArvind Kush
Arvind KushExecutive
TLTimothy Lu, M.D.
Timothy Lu, M.D.Executive
BH
Bernie Huyghe, Ph.D.Executive

Board

JT
Jeffrey Tong, Ph.D.Board director
AR
Aaron Royston, M.D.Board director
MR
Michael Rome, M.D.Board director

Investors · 9

LifeSci Venture Partnerslisted by LifeSci Venture PartnersNew York

How we know: LifeSci Venture Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us

Samsara BioCapitallisted by Samsara BioCapitalMenlo Park

How we know: Samsara BioCapital's portfolio page · Not right? Tell us

TCG Crossoverlisted by TCG CrossoverPalo Alto
Third Rock Ventureslisted by Third Rock VenturesBoston · $100K – $5M

How we know: Third Rock Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

venBio Partnerslisted by venBio PartnersSan Francisco

How we know: the VCSheet dataset · Not right? Tell us

Vida Ventureslisted by Vida VenturesLos Angeles

How we know: Vida Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Qiming Venture PartnersreportedBeijing

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$206.2M disclosed across 1 round · 2024

▶$206.2MraisedSep 2024 · 33 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey Tong, Ph.D.Director
  • Arvind KushExecutive Officer
  • Timothy Lu, M.D.Executive Officer
  • Kenneth Song, M.D.Executive Officer, Director
  • Aaron Royston, M.D.Director
  • Bernie Huyghe, Ph.D.Executive Officer
  • Michael Rome, M.D.Director
Offering amount
$206.2M
Amount sold
$206.2M
First sale
Aug 2024
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Candid Therapeutics went on to found or lead other companies.

Angie YouIndependent Board MemberFounded Amunix Pharmaceuticals +1Ken SongChairman, President and CEOFounded Rayze Bio

Related companies · 3

ObsidiantxObsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.

Companies working in the same space as Candid Therapeutics.

In the news

Candid Therapeutics Raises $370M in Fundingfinsmes.com · Sep 2024

Frequently asked questions

What does Candid Therapeutics do?
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells. The company focuses on creating therapies that are more effective and easier to administer than existing antibody and cell therapy approaches.
Who founded Candid Therapeutics?
Candid Therapeutics was founded by Ken Song, Kenneth Song, M.D. in 2024.
Who are Candid Therapeutics's investors?
Candid Therapeutics's investors include Foresite Capital, LifeSci Venture Partners, OrbiMed, Samsara BioCapital, TCG Crossover, Third Rock Ventures, venBio Partners, Vida Ventures and 1 more.
How much funding has Candid Therapeutics raised?
Candid Therapeutics has disclosed $206.2M raised across 1 round.
Where is Candid Therapeutics headquartered?
Candid Therapeutics is headquartered in San Diego, US.